TY - JOUR
AR - SCR-2021-8-121
TI - Cecal Perforation in a COVID-19 Patient Treated with Tocilizumab: A Case Report
AU - Victor, Dominguez Prieto
AU - Cecilia, Meliga
AU - Sara, Rosenstone
AU - Siyuan, Qian Zhang
AU - Manuel, Escanciano Escanciano
AU - Felipe, Velez Pinto
AU - Sergio Hernandez, Villafranca
AU - Sara Gonzalez, Soares
AU - Javier, Barambio Buendia
AU - Miguel, Leon Arellano
AU - Damian Garcia, Olmo
AU - Ricardo, Pardo Garcia
AU - Hector, Guadalajara Labajo
JO - Surgical Case Reports
PY - 2021
DA - Thu 09, Sep 2021
SN - 2613-5965
DO - http://dx.doi.org/10.31487/j.SCR.2021.08.21
UR - https://www.sciencerepository.org/cecal-perforation-in-a-covid-19-patient-treated-with-tocilizumab_SCR-2021-8-121 
KW - COVID-19, tocilizumab, interleukin-6, gastrointestinal perforation
AB - Tocilizumab is a monoclonal antibody against the interleukin-6 receptor. Gastrointestinal perforation has been associated with Tocilizumab treatment. In the absence of specific antiviral drugs, Tocilizumab is currently being used as a treatment option in patients with severe COVID-19 pneumonia. This is being based on the implication of interleukin-6 in the aberrant host immune response that characterizes the disease and initiates patients' lung damage. Herein we present the case of a cecal perforation in a patient treated with Tocilizumab for COVID-19. In such context, we expect that there may be an increase in the incidence of gastrointestinal perforation related to Tocilizumab.